Department of Pathology & Laboratory Medicine, 231 Albert Sabin Way, University of Cincinnati, OH 45267-0529, USA.
Regen Med. 2010 Nov;5(6):919-32. doi: 10.2217/rme.10.65.
Stem cells provide an alternative curative intervention for the infarcted heart by compensating for the cardiomyocyte loss subsequent to myocardial injury. The presence of resident stem and progenitor cell populations in the heart, and nuclear reprogramming of somatic cells with genetic induction of pluripotency markers are the emerging new developments in stem cell-based regenerative medicine. However, until safety and feasibility of these cells are established by extensive experimentation in in vitro and in vivo experimental models, skeletal muscle-derived myoblasts, and bone marrow cells remain the most well-studied donor cell types for myocardial regeneration and repair. This article provides a critical review of skeletal myoblasts as donor cells for transplantation in the light of published experimental and clinical data, and indepth discussion of the advantages and disadvantages of skeletal myoblast-based therapeutic intervention for augmentation of myocardial function in the infarcted heart. Furthermore, strategies to overcome the problems of arrhythmogenicity and failure of the transplanted skeletal myoblasts to integrate with the host cardiomyocytes are discussed.
干细胞通过补偿心肌损伤后继发的心肌细胞丢失，为梗死心脏提供了一种替代性的治疗干预方法。心脏中存在常驻的干细胞和祖细胞群体，以及体细胞的核重编程，通过遗传诱导多能性标志物，这是基于干细胞的再生医学的新兴新进展。然而，在体外和体内实验模型中进行广泛的实验，以及在安全性和可行性方面建立这些细胞之前，骨骼肌源性成肌细胞和骨髓细胞仍然是心肌再生和修复的最广泛研究的供体细胞类型。本文根据已发表的实验和临床数据，对骨骼肌成肌细胞作为移植供体细胞进行了批判性评价，并深入讨论了基于骨骼肌成肌细胞的治疗干预在增强梗死心脏心肌功能方面的优缺点。此外，还讨论了克服成肌细胞的致心律失常性和与宿主心肌细胞整合失败的问题的策略。
